Market news

LATHAM, N.Y., September 28, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2027 before the market open on Thursday, October 8, 2026. The Company’s management will host a conference call at 8:00 am ET the same day to discuss the results.

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AngioDynamics (NASDAQ:ANGO) expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and toward higher-growth medical technology platforms, executives said during a Canaccord fireside chat

2026-08-11. The following slide deck was published by AngioDynamics, Inc.

LATHAM, N.Y., July 28, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its management team is scheduled to participate in the following upcoming investor conferences:

Med Tech revenue surged 16.7% as company shifts toward higher-margin products.

Detailed price information for Angiodynamics Inc (ANGO-Q) from The Globe and Mail including charting and trades.

Moby summary of AngioDynamics, Inc.'s Q4 2026 earnings call

ANGO's Q4 FY26 revenues rise 8% as Med Tech surges, while its adjusted loss beats estimates and FY27 sales guidance tops consensus.

Detailed price information for Angiodynamics Inc (ANGO-Q) from The Globe and Mail including charting and trades.

AngioDynamics (ANGO) delivered earnings and revenue surprises of +36.36% and +7.61%, respectively, for the quarter ended May 2026. Do the numbers hold clues to what lies ahead for the stock?

LATHAM, N.Y. (AP) — AngioDynamics Inc. (ANGO) on Tuesday reported a loss of $11.4 million in its fiscal fourth quarter. On a per-share basis, the Latham, New York-based company said it had a loss of 27 cents. For the year, the company reported that its loss widened to $36.7 million, or 88 cents per share.

AngioDynamics (NASDAQ:ANGO) reported higher fiscal fourth-quarter and full-year revenue, driven by continued growth in its med tech portfolio, while management said the company remains focused on balancing investment in clinical programs with profitability and cash generation. On the company’s fisc

AngioDynamics Inc. (NASDAQ:ANGO) delivered stronger-than-expected fourth-quarter results on Tuesday, beating Wall Street forecasts for both revenue and adjusted earnings while issuing an upbeat sales outlook for fiscal 2027.